I-Mab Biopharma (IMAB) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts IMAB Hot Sheet
Join SI Premium – FREE
I-Mab Biopharma (NASDAQ: IMAB) reported Q3 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07).
For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Sigma Lithium resumes full operations after signing TAC agreement
Create E-mail Alert Related Categories
Earnings, Management ChangesRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
